Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Allogene Therapeutics logo — A biotechnology company catalyzing cancer treatment through...

Allogene Therapeutics

A biotechnology company catalyzing cancer treatment through the development of CAR T therapy

Founded 2017 United States South San Francisco, United States 214 employees IPO Total: $1.05B Biotechnology

General Information

Company Name Allogene Therapeutics
Founded Year 2017
Location United States South San Francisco, United States
Employees 214
Industries Biotechnology
Funding Stage IPO
Business Model B2B, B2C, B2D
Revenue Model Product Sales, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Allogene Therapeutics. To contact Allogene Therapeutics, visit allogene.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Allogene Therapeutics compare?

A PDF of Allogene Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Allogene Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Allogene Therapeutics

Allogene Therapeutics, based in South San Francisco, is a clinical-stage biotechnology company spearheading the evolution of cancer treatment with its innovative AlloCAR T products. Founded in 2017, the company is at the forefront of developing allogeneic chimeric antigen receptor T cell therapies, targeting both cancer and autoimmune diseases.

The company leverages its expertise to catalyze the future of immunotherapy by eliminating constraints posed by traditional autologous CAR T therapies, such as individualized production and lengthy wait times. This pioneering approach positions Allogene Therapeutics as a decisive player in the biotechnology landscape.

Allogene Therapeutics recently secured a significant $110M in Post Ipo Equity investment as of May 2024, underscoring continuous investor confidence in its visionary endeavors. As the company advances its pipeline, it remains a promising candidate for partnerships and further investment opportunities.

Business keywords: clinical-stage, cancer treatment, immunotherapy, CAR T therapy, AlloCAR T products, allogeneic therapies, oncology, autoimmune disease, cell therapy, therapy development, biopharmaceuticals, medical innovation, South San Francisco

Services & Products

Development of CAR T cell products
Clinical trial management
Gene editing and engineering
Manufacturing of allogeneic therapies
Therapeutic innovation for cancer and autoimmune diseases

Target Customers

Patients with blood cancers Patients with solid tumors Patients with autoimmune diseases Healthcare providers Biopharmaceutical partners

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $200.40M -
01 Apr 2026
Post-IPO Equity $110.00M -
01 May 2024
Series A $324.00M -
01 Oct 2018
Series A $411.80M 4
Two River Vida Ventures
Two River, Vida Ventures +2
01 Apr 2018

Allogene Therapeutics Alternatives & Competitors

View All Alternatives
Allogene Therapeutics vs
Adicet Bio, Inc
Adicet Bio, Inc United States

A biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR t cell...

IPO
124 employees
Biopharma, Biotechnology
Allogene Therapeutics vs
Century Therapeutics, Inc
Century Therapeutics, Inc United States

Advancing iPSC-derived cell therapies to transform care in autoimmune disease and cancer​

119 employees
Biotechnology
Allogene Therapeutics vs
Autolus Therapeutics
Autolus Therapeutics United Kingdom

Focused on the development of precisely targeted, controlled & highly active T cell therapies for ca...

Post-IPO Equity
720 employees
Biopharma, Biotechnology
Also compare with: Allogene Therapeutics vs Adaptimmune Adaptimmune View all alternatives

FAQ About Allogene Therapeutics

A biotechnology company catalyzing cancer treatment through the development of CAR T therapy
Allogene Therapeutics was founded in 2017.
Allogene Therapeutics is headquartered in South San Francisco, United States.
Allogene Therapeutics operates in Biotechnology. Its work centres on clinical-stage, cancer treatment, immunotherapy and CAR T therapy. Its customers include Patients with blood cancers, Patients with solid tumors and Patients with autoimmune diseases.
Allogene Therapeutics has a B2B, B2C and B2D business model. Its revenue comes from Product Sales, Licensing and Service Fee.
Allogene Therapeutics has approximately 214 employees.
Allogene Therapeutics has completed 4 funding rounds, raising a total of $1.05B. The latest funding stage is IPO.
Allogene Therapeutics offers: Development of CAR T cell products, Clinical trial management, Gene editing and engineering, Manufacturing of allogeneic therapies, Therapeutic innovation for cancer and autoimmune diseases.
Top alternatives and competitors to Allogene Therapeutics include Adicet Bio, Inc, Century Therapeutics, Inc, Autolus Therapeutics, Gracell Biotechnologies, Cartesian Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Allogene Therapeutics and Adicet Bio, Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Allogene Therapeutics, https://bouncewatch.com/company/allogene-therapeutics, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout